Clinical trials: Locally Advanced Gastric Cancer
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
This study is a prospective, open-label, phase II clinical trial that aims to enroll patients with locally advanced gastric adenocarcinoma who have not received any prior treatment and are candidates for surgery.
- Trial name
- NCT06385873
- Testing
- RC48, Adebrelimab, Apatinib
- Volunteers
- 32 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)
Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment
In Spain, the gastric carcinoma is the 5th most frequent malignant tumor in women and the 6th in men, and represents the 3rd cause of cancer-related deaths amongst women and the 4th amongst men.
- Trial name
- NCT01262482
- Testing
- Oxaliplatin, Sorafenib
- Where
- 10 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Gastric Cancer, Gastric Adenocarcinoma
Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer
The aim of the trial is to investigate the clinical efficacy and toxicity of perioperative chemotherapy with leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) in patients with locally advanced gastric or gastroesophageal junction…
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, Effects of Chemotherapy, Toxicity Due to Chemotherapy
- Trial name
- LOTS (NCT04999332)
- Testing
- leucovorin, oxaliplatin, docetaxel, S-1
- Where
- 4 sites in Taiwan
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- National Cheng-Kung University Hospital
Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
The purpose of the study is to compare the efficacy of Ipilimumab and standard of care as sequential or maintenance treatment immediately after first-line chemotherapy in the treatment of unresectable or metastatic gastric and…
- Trial name
- NCT01585987
- Testing
- Ipilimumab, Best Supportive care (BSC)
- Where
- 36 sites in United States, France and 10 more
- Volunteers
- 143 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Stomach Neoplasms, Neoadjuvant Therapy
A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma
This prospective, randomized phase II study is designed to evaluate weather neoadjuvant chemoradiotherapy is superior to neoadjuvant chemotherapy with both followed by surgery and postoperative chemotherapy for locally advanced…
- Conditions
- Stomach Neoplasms, Neoadjuvant Therapy, Chemoradiotherapy, Chemotherapy
- Trial name
- NCT02301481
- Testing
- SIB-IMRT, S-1, Surgery
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Chinese Academy of Medical Sciences
Gastric Cancer, Survival Rate
Effect of HIPEC After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer
The study focuses on patients with locally advanced gastric adenocarcinoma (cT3N+M0 and cT4aN+/-M0), assessing the feasibility, surgical safety, and oncological benefit of prophylactic HIPEC treatment following laparoscopic D2…
- Trial name
- NCT06525714
- Testing
- cisplatin oxaliplatin tegafur
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- The First Hospital of Jilin University
Gastric Cancer
Efficacy of Laparoscopic Subtotal Gastrectomy With D2 Lymph Node Dissection for Locally Advanced Gastric Cancer
It was confirmed that the laparoscopic surgery decreases the postoperative pain and reduces the recovery periods in the various surgical fields such as cholecystectomy and colectomy etc.
- Trial name
- KLASS-02-RCT (NCT01456598)
- Testing
- Laparoscopic gastrectomy, Open gastrectomy
- Where
- 13 sites in South Korea
- Volunteers
- 1,050 people
- Sponsor
- Ajou University School of Medicine
Gastric Cancer
Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer
The study is to evaluate the efficacy of Apatinib in patients with advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction.
- Trial name
- NCT02537171
- Testing
- apatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Gastric Cancer, Effects of Chemotherapy
FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer
Purpose: This aim of the study is to evaluate the efficacy and safety of neoadjuvant chemotherapy with the modified FOLFOX6(mFOLFOX6) regimen and its impact on survival on a series in local advanced gastric cancer patients.
- Conditions
- Gastric Cancer, Effects of Chemotherapy, Surgery
- Trial name
- FOLFOX6 (NCT02226380)
- Testing
- mFOLFOX6 regimen
- Where
- 2 sites in China
- Volunteers
- 75 people
- Sponsor
- Peking Union Medical College Hospital
Locally Advanced Gastric Cancer
Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
We plan to evaluate the efficacy and safety of proximal gastric vs. total gastric radical resection after SOX combined with anti-PD-1 neoadjuvant therapy in locally advanced upper gastric cancer
- Trial name
- TJHGC01 (NCT06597227)
- Testing
- Proximal radical gastrectomy, Total radical gastrectomy
- Where
- China
- Volunteers
- 404 people
- Sponsor
- Guihua Wang
Locally Advanced Gastric Carcinoma, HER2 Negative
Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer
This study objectively analyzes the safety and survival evaluation of perioperative immunotherapy combined with chemotherapy in locally advanced gastric cancer patients through a prospective randomized controlled trial research…
- Conditions
- Locally Advanced Gastric Carcinoma, HER2 Negative, Efficacy, Safety
- Trial name
- NCT06284746
- Testing
- Tirolizumab+SOX/XELOX, SOX/XELOX
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Lin Chen
Gastric Cancer
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer
To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.
- Trial name
- NCT05914610
- Testing
- Envolimab, Fruquintinib, Oxaliplatin
- Volunteers
- 100 people
- Sponsor
- Fujian Medical University
Gastric Cancer
Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer
This prospective cohort study aims to construct an artificial intelligence (AI)-derived predictive model for neoadjuvant chemotherapy response prediction in patients with locally advanced gastric cancer based on preoperative…
- Trial name
- NCT07697079
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Liu Yang
Gastric Carcinoma
XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma
This is a randomized, multicenter, controlled study to compared the Efficacy and Safety of XELOX combined with Apatinib versus XELOX as post-operative chemotherapy in locally advanced gastric signet ring carcinoma with D2…
- Trial name
- NCT03355612
- Testing
- Apatinib, XELOX
- Volunteers
- 456 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer, Gastric Cancer
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally…
- Trial name
- NCT00005876
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Gastric Cancer
Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial
The hypothesis of this study is that a radiotherapy dose of 36Gy in 12 fractions, which equates to a BED of 48.6Gy, increases the response rates of symptom relief compared to historical controls.
- Trial name
- NCT01341756
- Testing
- Palliative Radiotherapy
- Where
- Singapore
- Volunteers
- 63 people
- Sponsor
- National University Hospital, Singapore
Gastrointestinal Neoplasms, Gastric Cancer
A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer
The purpose of this study is to determine maximum tolerated dose (MTD), dose limiting toxicities (DLT) and recommend a proper dose for our phase II study of S-1 when combined with radiation therapy for locally advanced or…
- Trial name
- NCT01291407
- Testing
- S-1
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Chinese Academy of Medical Sciences
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
This study is designed to assess the safety and preliminary activity of SBT6050 in combination with trastuzumab deruxtecan (Part 1) or tucatinib plus trastuzumab +/- capecitabine (Part 2).
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
- Trial name
- NCT05091528
- Testing
- SBT6050, trastuzumab deruxtecan, tucatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Silverback Therapeutics
Gastric Cancer
CT Body Composition Enhances Survival Risk Stratification
Gastric carcinoma remains the fifth most common malignancy and the second leading cause of cancer-related mortality worldwide. For patients with locally advanced disease, standard treatment includes radical gastrectomy followed…
- Trial name
- NCT07109271
- Where
- Taiwan
- Volunteers
- 227 people
- Sponsor
- Chang Gung Memorial Hospital